OncoTargets and Therapy

Open Access Full Text Article

RETRACTION

MicroRNA-761 Targets FGFR1 to Suppress the Malignancy of Osteosarcoma by Deactivating PI3K/Akt Pathway [Retraction]

Lv Z, Ma J, Wang J, Lu J. Onco Targets Ther. 2019;12:8501–8513.

The Editor and Publisher of *OncoTargets and Therapy* wish to retract the published article. Concerns were raised over alleged image duplication in Figures 2C, 5C and 7A with similar images from unrelated articles, specifically:

- Figure 2C, panel HOS agomir-761 appears to have been duplicated with a similar image in Figure 5B from Wang et al, 2020 (<u>https://doi.org/10.1016/j.prp.</u>2020.152903).
- Figure 5C, panel HOS agomir-NC appears to have been duplicated with a similar image in Figure 5D from Chen et al, 2019 (https://doi.org/10.2147/OTT.S192137).
- Figure 5C, panel U2OS agomir-761+pCMV-FGFR1 appears to have been duplicated with a similar imges

in Figure 2E from Ye et al, 2020 (<u>https://doi.org/10.</u> 2147/CMAR.S228429).

• Figure 7A, appears to have been duplicated with similar images in Figure 7B from Song et al, 2018 (http://www.ajcr.us/files/ajcr0088433.pdf).

The authors did not respond to our queries and the Editor determined the findings of the study were no longer valid and advised for the article to be retracted.

Our decision-making was informed by our policy on publishing ethics and integrity and the COPE guidelines on retraction.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as "Retracted".

OncoTargets and Therapy

Dovepress

Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/ testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/oncotargets-and-therapy-journal

http://doi.org/10.2147/OTT.S340637

Received: 22 September 2021 Accepted: 22 September 2021 Published: 28 September 2021

OncoTargets and Therapy 2021:14 4937

4937

© 2021 Dove Medical Press. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/ the work you hereby accept the Terms.Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission from Dove Medical use of this work, please see paragraphs 4.2 and 5 of our Terms (http://www.dovepress.com/terms.php).